<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114219">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01784367</url>
  </required_header>
  <id_info>
    <org_study_id>PV4190</org_study_id>
    <nct_id>NCT01784367</nct_id>
  </id_info>
  <brief_title>Extracorporeal Lung Assist to Avoid Intubation in Patients Failing Noninvasive Ventilation for Acute Hypercapnic Respiratory Failure</brief_title>
  <acronym>ECLAIR</acronym>
  <official_title>Extracorporeal Lung Assist to Avoid Intubation in Patients Failing Noninvasive Ventilation for Acute Hypercapnic Respiratory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <authority>Germany: Ethics commitee of the Medical Association Hamburg</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study´s intention is to evaluate the feasibility, safety and effectiveness of a pump
      driven extracorporeal device for removal of carbon dioxide from the blood in oder to avoid
      intubation and invasive mechanical ventilation in patients with acute respiratory failure
      retaining carbon dioxide due to the failure of their ventilatory muscle pump and not
      responding to prior non-invasive mask ventilation. Since intubation with subsequent
      (prolonged) invasive mechanical ventilation is associated with considerable side effects
      this new strategy has the potential to improve overall clinical outcome in this selected
      patient group.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of intubation for invasive mechanical ventilation</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of non-invasive ventilation</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rates</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Any complication associated with the pump driven extracorporeal lung assist device or with non-invasive or invasive mechanical ventilation or any associated treatments during the observational period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of invasive mechanical ventilation if intubated</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in ICU and hospital</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood gases and respiratory rate pre/post start of ECLA</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in arterial blood gases before and after the initiation of the pump driven extracorporeal lung assist</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hypercapnia</condition>
  <condition>Respiratory Insufficiency</condition>
  <arm_group>
    <arm_group_label>ECLA-group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients included in the study receiving treatment with a pump driven, venovenous extracorporeal lung assist (ECLA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ECLA (extracorporeal lung assist)</intervention_name>
    <description>Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.</description>
    <arm_group_label>ECLA-group</arm_group_label>
    <other_name>Name of device: iLA-Activve</other_name>
    <other_name>Manufacturer: Novalung GmbH, Germany</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  acute or acute-on-chronic hypercapnic respiratory insufficiency (pH ≤ 7,35, PaCO2 &gt;
             45 mmHg)

          -  failure of noninvasive ventilation

          -  fulfilling criteria for endotracheal intubation

        Exclusion Criteria:

          -  under 18 years of age

          -  prior inclusion in other interventional study

          -  pregnancy

          -  heparin allergy or heparin-induced thrombocytopenia type 2

          -  on home non-invasive ventilator

          -  &quot;Do not resuscitate&quot; order or moribund condition

          -  life expectancy less than 6 months

          -  no informed consent available
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan Kluge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Intensive Care Medicine, University Medical-Center Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefan Kluge, MD</last_name>
    <phone>+4940741057010</phone>
    <email>skluge@uke.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephan A Braune, MD, MPH</last_name>
    <phone>+4915222817083</phone>
    <email>sbraune@uke.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Intensive Care Medicine, University Medical-Center Hamburg-Eppendorf (plus 10 further centres in Germany, Austria and the Netherlands)</name>
      <address>
        <city>Hamburg</city>
        <zip>22399</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Kluge, MD</last_name>
      <phone>+49741057010</phone>
      <email>skluge@uke.de</email>
    </contact>
    <contact_backup>
      <last_name>Stephan A Braune, MD, MPH</last_name>
      <phone>+4015222817083</phone>
      <email>sbraune@uke.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stefan Kluge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephan A Braune, MD, MPH</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Axel Nierhaus, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uke.de/kliniken/intensivmedizin</url>
    <description>Department of principal investigator</description>
  </link>
  <reference>
    <citation>Kluge S, Braune SA, Engel M, Nierhaus A, Frings D, Ebelt H, Uhrig A, Metschke M, Wegscheider K, Suttorp N, Rousseau S. Avoiding invasive mechanical ventilation by extracorporeal carbon dioxide removal in patients failing noninvasive ventilation. Intensive Care Med. 2012 Oct;38(10):1632-9. Epub 2012 Jul 27.</citation>
    <PMID>22836139</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>January 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitätsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Stefan Kluge</investigator_full_name>
    <investigator_title>PD Dr. Stefan Kluge</investigator_title>
  </responsible_party>
  <keyword>Hypercapnia</keyword>
  <keyword>noninvasive ventilation</keyword>
  <keyword>acute respiratory failure</keyword>
  <keyword>endotracheal intubation</keyword>
  <keyword>invasive mechanical ventilation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercapnia</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Hypoventilation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
